Skip to content

    Recently Viewed

      Listening...

      Home / Latest news /
      Johnson & Johnson makes Fortune‘s 2017 Change the World list
      A photo of Alex Gorsky and Pat Gorksy with mMitra families in India

      Johnson & Johnson makes Fortune‘s 2017 Change the World list

      The company nabs the #9 spot this year for helping to decrease mother and baby mortality rates in India through the mMitra program.

      Share Article
      share to

      For the second year in a row, Johnson & Johnson has been nominated to the annual Fortune Change the World list, which spotlights 50 top companies globally that have had a “positive social impact through activities that are part of their core business strategy.”

      Johnson & Johnson was recognized for its work with mMitra, an innovative mobile-messaging program that sends vital health information to expectant and new mothers living in low-income urban communities in India.

      The company ranks #9 on the list this year—up over 20 spots from its #31 ranking on the 2016 list for its work to help combat tuberculosis.

      This latest recognition for Johnson & Johnson comes on the heels of being named a Most Admired Company by Fortune in February, underscoring its reputation as one of the best companies to work for.

      How mMitra is making a difference

      Johnson & Johnson spearheaded mMitra (short for “mobile friend” in Hindi) in 2014, in partnership with the Mobile Alliance for Maternal Action, ARMMAN, the U.S. Agency for International Development, the United Nations Foundation and BabyCenter®.

      Their shared goal: help the roughly 150 mothers and 3,500 children under the age of 5 who die each day in India from pregnancy complications or early childhood disease. Such grim statistics are due, in part, to a lack of accessibility to basic health information.

      A study conducted by the Foundation for Research in Health Systems on the communities using mMitra showed an increase in antenatal visits and baby immunization rates, as well as earlier registrations of pregnancies.

      Since most women throughout India have access to a mobile phone, the thinking with mMitra was that women could get free calls and texts in their dialect providing expert health and preventative care information tailored to a mom’s stage of pregnancy or a child’s development.

      “There were limited models of this type of program, and definitely none at scale,” says Alice Lin Fabiano, Johnson & Johnson’s Director of Global Community Impact. “We were the first in the private sector to do something like this in multiple global locations specifically targeting low-income families.”

      The results are certainly heartening.

      More than 1 million mothers in India have since participated, and an independent study conducted by the Foundation for Research in Health Systems on the communities using mMitra showed an increase in antenatal visits and baby immunization rates, as well as earlier registrations of pregnancies.

      And there’s even more planned for mMitra, which is now available in more than 10 countries, including South Africa, Malawi and Mexico.

      “We’re now looking at technology beyond voice and text,” Fabiano says. “Videos and visuals will increase the effectiveness of the message and the sustainability of the program.”

      More from Johnson & Johnson

      Innovation
      Headshots of three Johnson and Johnson female scientists

      Meet 3 leaders who are breaking new ground for women in healthcare

      For International Women’s Day, celebrate the achievements of these amazing female scientists and researchers at Johnson & Johnson.
      Innovation
      Close-up of a woman with low vision receiving an eye exam exam with a doctor shining light into her left eye

      What is low vision?

      Low vision isn’t the same as blindness, but navigating daily life with it is still challenging. For Low Vision Awareness Month, learn the facts—plus, the promising treatment innovations that are in the works.
      Innovation
      A female scientist conducting research in a laboratory, focusing on orphan drugs for rare diseases

      What is an orphan drug?

      The need for these rare disease therapies is strong, and access to them can be lifesaving. Here’s how Johnson & Johnson is innovating to help give patients options.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.